E Ink and LTS Partner to Develop Smart Patch to Improve Medical Management
E Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, “LTS” leading in the development and manufacturing of transdermal therapeutic systems, today announced their partnership to develop a “Smart Patch” prototype. The Smart Patch prototype is a transdermal therapeutic system (TTS) that delivers medication to patients in a convenient, controlled and comfortable manner and features an E Ink display to deliver and convey relevant information about patch performance.
This press release features multimedia. View the full release here:
The “Smart Patch” prototype features an E Ink display to convey relevant information about patch performance to patients. (Photo: E Ink Holdings)
According to a report conducted by the New England Healthcare Institute (NEHI), poor medication adherence is a pervasive problem that costs $290 billion a year in the U.S. Forgetting to take medication and not understanding administration instructions are among the main reasons why between 20 and 50 percent of patients are not adhering to their medical regimens. Smart drug systems like Smart Patches will increase globally to nearly $81.4 billion by 2024 as they provide a more targeted, uniform and secure method of drug delivery.
“Poor medical adherence negatively impacts patients’ therapeutic outcomes, leading to more hospitalizations and higher total costs,” said Dr. Hanshermann Franke, Corp. VP of R&D at LTS. “The main purpose of any innovation must be centered on the idea of making patients’ lives as healthy and comfortable as possible. This can be achieved by designing “smart” solutions that easily integrate, facilitate treatment monitoring and help patients use their medication properly.”
The Smart Patch is equipped with a 2” E Ink electronic paper display (EPD) that leverages the display’s bistable nature to ensure the patient doesn’t need to recharge the battery. The patch features a switch, pressure sensor and a low voltage E Ink display that shows helpful information with functionalities including:
- A message indicating whether the patch is applied correctly to the skin
- A countdown until the next dose
- A reminder to remove the patch and to replace it appropriately
“This is the first application to feature E Ink’s low voltage film, which uses 50-70 percent of the typical driving voltage for EPDs,” said Dr. FY Gan, EVP of Sales Center at E Ink. “In addition to minimizing power consumption, which results in the ability to use a small battery with a longer battery life, the low voltage film is the thinnest electronic paper film available on the market at less than 200um, enabling it to fit flawlessly on the TTS.”
“There are many advantages to TTS technologies, and now we can add a decisive enhancement – an E Ink display,” said Dr. Tim Schlange, CMO at LTS. “This feature allows LTS to provide functionalities to patients with more reliable, safe and pain-free applications and to further enhance the value of solutions for its partners in the pharmaceutical industry.”
“Medical innovation is happening at an unprecedented rate and we are excited to partner with a company that is providing unique drug delivery systems in the marketplace to improve medical compliance,” said Dr. Paul Apen, Chief Strategy Officer at E Ink. “Our displays are a natural fit for this type of drug delivery system as they are thin, have a wide viewing angle and consume minimal power for continued use. This is just one of the ways our display technology is impacting the future of medical applications.”
The Smart Patch concept will initially target the treatment of chronic diseases. The first prototype will be displayed during CPhI in Messe Frankfurt, Germany October 24-26, 2017 at LTS’s booth 4.0 C40.
For more information or to speak with a sales representative, visit www.EInk.com.
About E Ink Holdings
E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market and is redefining the signage, architecture and design, mobile, wearable and retail markets with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com.
About LTS Lohmann Therapie Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS’s innovation model consists of both partner-funded and self-funded initiatives currently encompassing more than 20 marketed products and a deep and diverse pipeline of development projects targeting multiple disease indications. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.
Lauren Ginsberg, +1 617-624-3254
LTS Marketing und Market Services
Dr. Iris Schnitzler, +49 (0) 2632 99 – 2589
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Indian Detective, Starring Russell Peters, Premieres Tuesday, December 19, 2017 on Netflix Worldwide20.11.2017 16:00 | Pressemelding
Full release here. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005203/en/ (Photo: Business Wire) Following today’s announcement by Netflix, THE INDIAN DETECTIVE , a four-part comedy-drama series starring international comedy sensation Russell Peters, award-winning actor Anupam Kher (The Big Sick, Silver Linings Playbook), the iconic William Shatner (Star Trek), Christina Cole (Suits, Casino Royale), Hamza Haq (mother!, Bon Cop, Bad Cop 2), Akshay Kumar (Star Wars Ep VIII), Meren Reddy (Madiba, Homeland) and Mishqah Parthiephal (Keeping Up with the Kandasamys, Snake Park), will premiere on December 19, 2017 on Netflix worldwide, following an initial run on CTV Canada in November.
Andersen Global Expands Presence in Italy with New Location in Venice-Mestre, on the Venetian Mainland20.11.2017 14:30 | Pressemelding
Andersen Global is proud to announce a new presence in Venice-Mestre, on the Venetian mainland in Italy through the expansion of Italian member firm, Andersen Tax & Legal. In addition, the Milan office will relocate at the end of November. The new office in Mestre and new location in Milan have been established to better serve the growing client base in Italy. Andersen Tax & Legal now has six locations in Italy: Milan, Brescia, Rome, Venice, Mestre, and Monza. Andrea De Vecchi, Office Managing Partner of Andersen Tax & Legal in Italy, and Regional Managing Partner in Europe shared, “Our new location in Venice-Mestre and expanded presence in Milan allow us to better serve our clients and continue to build our capabilities within the region. Through this expansion, we are able to reach new markets and also improve the quality of life for our employees.” Venice-Mestre is a sign
NexPlayer HTML5 Player Fully Compatible with Conviva across All Browsers and Devices20.11.2017 14:00 | Pressemelding
NexStreaming, the provider of NexPlayer SDK, the market leader player SDK for OTT apps, announced today that the NexPlayer HTML5 player is fully compatible with Conviva Video AI Platform. This pre-integrated solution brings great value to video services: from now on, they will be able to enable the highest quality HLS & DASH live streaming across all browsers and devices with NexPlayer, and ensure an outstanding user experience with accurate analytics about the quality of the video experience thanks to Conviva. In this technology integration, NexPlayer HTML5 is fully optimized with Conviva’s QoE analytics. NexPlayer sends information regarding the use of the HTML5 based OTT service, including when the user pauses the video or the video is buffering as well as information about the frame-rate. Conviva measures and analyzes this information so that video service providers and publishers
AGCO’s Innovation Rewarded with Prestigious Awards at Agritechnica 201720.11.2017 14:00 | Pressemelding
AGCO, Your Agriculture Company, (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment and solutions, achieved remarkable success with 17 major awards at the prestigious Agritechnica 2017 event in Hannover, Germany. As a result of the votes cast by an independent expert committee, AGCO was once again one of the most successful manufacturers at Agritechnica 2017 by way of the number of innovation awards received. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005614/en/ The new Fendt Track Tractor 943 Vario MT won the treasured award "Machine of the Year 2018" in the Category XXL Tractors (Photo: Business Wire) “Winning these significant awards is a testament to our continued commitment to deliver high-tech solutions for farmers feeding the world,” said Martin Richenhagen
Leading Broker ActivTrades Wins Le Fonti Forex Broker of the Year Award for the Second Time20.11.2017 13:30 | Pressemelding
ActivTrades, one of the world’s leading online Forex Brokers, has won the Le Fonti Forex Broker of the Year Award for the second year running. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005576/en/ ActivTrades was awarded at the Le Fonti Awards (Photo: Business Wire) A UK-regulated firm with offices in Europe and the Middle East, ActivTrades was selected as the winner by the editorial staff of over 120 journalists at Le Fonti, the international and independent media company and research centre. Le Fonti credited the broker for “aiming to maximise its clients’ trading through a unique mix of superior value proposition, diverse product offering and stellar customer service”. Le Fonti’s judges added that ActivTrades offers “some of the tightest spreads in the industry” a
European Commission Extends License for Janssen’s ZYTIGA® Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients20.11.2017 13:30 | Pressemelding
Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has granted approval to broaden the existing marketing authorisation for ZYTIGA® (abiraterone acetate) plus prednisone / prednisolone to include an earlier stage of metastatic prostate cancer than its current indications. Abiraterone acetate plus prednisone / prednisolone can now be used for the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).1 “Prostate cancer is the most common form of cancer in men throughout Europe and today’s decision helps to fill a critical medical need for these patients. We hope to significantly improve the lives of many men across Europe living with this disease and the approval of this treatment in an earlier stage of prostate cancer helps address this,”
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom